Combination chemotherapy of ovarian carcinoma with cisplatinum and treosulfan--a phase II study

Br J Obstet Gynaecol. 1985 Jul;92(7):762-7. doi: 10.1111/j.1471-0528.1985.tb01462.x.


Twenty-one patients with advanced ovarian carcinoma were treated with a combination of cisplatinum and treosulfan. The overall response rate by clinical and ultrasound assessment was 86%, but ultrasound was less optimistic in assessing 'completeness' of response (48% compared with 67% clinically). The median actuarial survival was 21 months. There was a 54.9% probability of survival at 43 months in those patients with a complete response and a median survival of 15 months in patients with a partial response. The data suggest that while short-term survival may depend upon the extent of residual disease, longer-term survival is determined by response to chemotherapy. The only toxicity of note was haematological.

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Busulfan / administration & dosage
  • Busulfan / adverse effects
  • Busulfan / analogs & derivatives
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Drug Evaluation
  • Female
  • Follow-Up Studies
  • Humans
  • Middle Aged
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / mortality


  • treosulfan
  • Busulfan
  • Cisplatin